Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04302025 · ClinicalTrials.gov registry record · Phase 2
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 20
- Study locations
NCT04302025 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Genentech. The registered enrollment target is 99 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT04302025, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
Conditions Studied
Interventions
- DRUG Vemurafenib
- DRUG Alectinib
- DRUG Entrectinib
- DRUG Cobimetinib
- DRUG Pralsetinib
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- City of Hope - Orange County Lennar Foundation Cancer Center - Irvine
- USC Norris Cancer Center - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- University of California Los Angeles - Jonsson Comprehensive Cancer Center - Los Angeles
- The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange - Orange
- UC Davis Comprehensive Cancer Center - Sacramento
- UCSF Helen Diller Family CCC - San Francisco
Illinois
- Northwestern University - Chicago
- Northwestern Medicine Cancer Center Kishwaukee - DeKalb
- Northwestern Medicine Cancer Center Delnor - Geneva
- Northwestern Medicine Cancer Center Warrenville - Warrenville
Massachusetts
- Boston Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Michigan
- University of Michigan - Ann Arbor
- Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center - Farmington Hills
Colorado
- University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center) - Aurora
Connecticut
- Yale Cancer Center - New Haven
District of Columbia
- MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center) - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2020-11-06 |
| Est. Completion | 2030-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04302025
The ClinicalTrials.gov registry entry for NCT04302025 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Vemurafenib is the first listed.
NCT04302025 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04302025 about?
NCT04302025 is a clinical study titled "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)". This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
What is the current status of trial NCT04302025?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2020-11-06. Estimated completion is 2030-05-30.
What conditions does trial NCT04302025 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT04302025?
The interventions under investigation include: Vemurafenib (DRUG), Alectinib (DRUG), Entrectinib (DRUG), Cobimetinib (DRUG), Pralsetinib (DRUG).
Who is sponsoring clinical trial NCT04302025?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04302025 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.